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Purpose: Osteoarthritis (OA) is the most prevalent arthritis worldwide. The chronic nature 
of OA often leads to long-term disability, with pain being a major symptom for which people 
seek care. During established OA disease, chronic pain due to cartilage, synovial and bone 
damage may be aggravated by the process of “central sensitisation”, whereby pain 
processing pathways in the central nervous system (CNS) become sensitised to peripheral 
nerve stimulation caused by degenerative and inflammatory disease processes. Our study 
aimed to establish if there are distinct brain regions activated during painful hand OA which 
could be used as a biomarker of OA pain. 
Methods: We conducted a brain neuroimaging study using a Philips 3 Tesla (3T) magnetic 
resonance imaging (MRI) scanner. A total of 46 participants were enrolled into the study 
after obtaining full informed consent. We investigated whether biochemical changes in the 
brain detectable by 1H Magnetic Resonance Spectroscopy (MRS) are related to clinical 
measures of perceived pain and related symptoms. 1H MRS was performed in the anterior 
cingulate cortex and the insula cortex , which are brain regions involved in pain processing 
and implicated in central sensitisation identified from our previous work. LCModel™ was 
used to quantify metabolites and metabolite ratios were used to avoid the confound of 
variable CSF fraction in the voxel. Quantified metabolites included myo-Inositol (mI), an 
inflammatory biomarker and the neurotransmitters Glx (total of neurotransmitters 
glutamate and glutamine). Clinical scores were measured using the 100 mm visual analogue 
scale (VAS) for pain, the Australian and Canadian Hand Osteoarthritis Index (AUSCAN) and 
the Hospital Anxiety and Depression Scale (HADS).  
Results: The age range of the recruited participants was 43 to 76 years, with all OA 
participants fulfilling ACR criteria for hand OA. Our study comprised n=32 participants with 
painful hand OA with a VAS scoring of at least 50 mm. Our control group (n=14) were age- 
and sex-matched participants with no history of hand OA or pain. Our MRS analysis 
demonstrated that there were no metabolite differences between controls and OA 
participants in the anterior cingulate gyrus, nor age related changes. In contrast, in the 
insula cortex the myo-Inositol/glutamate/glutamine (mI/Glx) ratio correlated with age (R2 = 
0.29, p = 0.0018) and correlated with the VAS pain score (R2 = 0.52, p = 0.018) after co-
varying for age. In addition, principal component analysis (PCA) across all clinical scores 
relating to pain and depression indicated the VAS pain score and AUSCAN stiffness scores 
correlated to the mI/Glx (p = 0.041) with age as a covariate.  
Conclusion: In conclusion, high mI/Glx in the insula cortex of hand OA participants is 
associated with high pain, and the age dependence of mI/Glx, suggests age dependent 
and/or duration dependent effects of OA on the brain. Our data show that distinct brain 
biomarkers are elevated specifically in the insula during chronic OA and could be useful in 
characterising OA pain. 
